- Home
- ZJYL vs TVRD Comparison
ZJYL vs TVRD Comparison
Compare ZJYL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZJYL | TVRD |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 37.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZJYL | TVRD |
|---|---|---|
| Price | $0.14 | $3.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 1.4M | 83.6K |
| Earning Date | 08-20-2025 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $22,826,624.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.05 | ★ N/A |
| Revenue Growth | ★ 13.42 | N/A |
| 52 Week Low | $0.11 | $3.74 |
| 52 Week High | $1.03 | $43.65 |
Technical Indicators
Market Signals| Indicator | ZJYL | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 36.25 |
| Support Level | $0.13 | $3.84 |
| Resistance Level | $0.18 | $4.07 |
| Average True Range (ATR) | 0.03 | 0.26 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 47.19 | 8.18 |
Price Performance
Historical ComparisonAbout ZJYL JIN MEDICAL INTERNATIONAL LTD.
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.